article thumbnail

2021 AAN highlight impact and breadth of expanding neuroscience portfolio

The Pharma Data

Roche will present data on the increased use of home nursing capabilities in the Phase III GRADUATE studies of gantenerumab during the COVID-19 pandemic, which enabled home-bound trial participants to continue dosing to maintain medicine exposure. Alzheimer’s Disease (AD). P1: Aging and Dementia: Biomarkers.

article thumbnail

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

The Pharma Data

protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological Na V 1.1 Participants continue to receive their usual care, and will be observed by a team of doctors and nurses over time for up to two years. .–( BUSINESS WIRE )– Stoke Therapeutics , Inc.